What is Michelson Diagnostics?
Founded in 2006, Michelson Diagnostics is a specialized provider of Optical Coherence Tomography (OCT) systems, most notably the VivoSight Dx Pro. The company operates at the intersection of clinical dermatology and advanced photonics, delivering high-resolution imaging solutions that facilitate rapid, accurate assessment of skin health. With a footprint established in over 700 peer-reviewed publications, the firm serves a diverse clientele of dermatologists, clinical researchers, and specialized medical facilities. Their technology is engineered to bridge the gap between complex laboratory research and practical, bedside clinical application, thereby enhancing diagnostic precision in skin cancer detection and general dermatological care.
How much funding has Michelson Diagnostics raised?
Michelson Diagnostics has raised a total of $7.1M across 2 funding rounds:
Series A
$3.3M
Series B
$3.8M
Series A (2014): $3.3M with participation from Turner Investments and Catapult Venture Managers Ltd
Series B (2015): $3.8M led by Catapult Venture Managers Ltd and Turner Investments
Key Investors in Michelson Diagnostics
Catapult Venture Managers Ltd
Catapult Ventures provides tailored investment solutions designed to support entrepreneurs in realizing their business ambitions. The firm focuses on fostering long-term growth through strategic partnerships and creative value generation.
Turner Investments
Turner Investments specializes in comprehensive financial research and quantitative analysis across multiple asset classes. They empower clients to navigate complex market risks by providing high-quality, accessible investment insights.
What's next for Michelson Diagnostics?
With the recent infusion of capital, Michelson Diagnostics is well-positioned to accelerate its enterprise-level expansion and further refine its diagnostic imaging suite. The strategic focus will likely shift toward increasing market penetration in global clinical settings and enhancing the software capabilities of the VivoSight platform. As the demand for non-invasive, high-fidelity diagnostic tools grows, the company is expected to leverage its established research credibility to secure a larger share of the medical imaging market. Future initiatives will likely prioritize the integration of advanced data analytics into their existing hardware, ensuring that clinicians receive actionable insights with greater efficiency, thereby cementing the company's role as a leader in the future of dermatological diagnostics.
See full Michelson Diagnostics company page
